Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- NuvaRing campaign
- Organon USA has launched its first direct-to-consumer advertising campaign for NuvaRing. The initiative is designed to educate consumers on the benefits and risks of the low-dose contraceptive, made in the form of a vaginal ring. The contraceptive is said to protect against pregnancy for an entire month.
- Research articles 2005-11-21
- Organon USA sells portion of West Orange headquarters
- Andrew B. Zezas, SIOR, president of Real Estate Strategies Corporation announced that Organon USA, Inc., a long time client of Real Estate Strategies Corporation and a business unit of the Pharma division of Akzo Nobel, NV based in The Netherlands, sold a portion of the Company's former headquarters and pharmaceutical...
- Research articles 2005-10-19
Additional Resources
- Organon USA to pay $36M to settle claims, class action suit
- New Jersey-based drug maker Organon USA Inc. and its Dutch parent, Akzo Nobel N.V., have agreed to pay $36 million to settle claims brought by state attorneys general and a private class action, Maryland Attorney General J. Joseph Curran Jr. announced yesterday. A federal court must approve the settlement. The...
- Research articles 2004-10-22
- Missouri Atty. General announces settlement with drug maker Organon
- Missourians who bought the anti-depressant drug Remeron could soon receive refunds under a nationwide settlement announced Monday by Attorney General Jay Nixon. Nixon and attorneys general from across the nation filed a preliminary settlement with drug maker Organon USA Inc. and its parent company, Akzo Nobel N.V., in New Jersey...
- Research articles 2004-11-03
- R.E. & CONSTRUCTION: Organon Opens World Headquarters in NJ
- Organon Pharmaceuticals combines its U.S. and worldwide headquarters at a 443,000 square-foot Roseland facility. The drug company's international headquarters had been located in the Netherlands, but it made the move for better synergies and a further commitment to the U.S. and the New Jersey pharmaceutical marketplace, according to Michael Novinski,...
- Research articles 2003-07-01
- Savient Pharmaceuticals Finalizes Agreement for the Settlement of Mircette® Litigation; Transaction Terminates Patent Litigation and Results in $13.75 Million Payment To Savient
- EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc. ("Savient") (NASDAQ: SVNTE), an emerging specialty pharmaceutical company engaged in developing, manufacturing and marketing pharmaceutical products that address unmet medical needs in niche and broader markets, announced today that it has concluded with Barr Pharmaceuticals, Inc. ("Barr") (NYSE: BRL), Organon USA Inc. and...
- Research articles 2005-12-02
- Drug settlement declared
- Utahns who have taken the antidepressant drug Remeron may be eligible for monetary compensation as part of a $36 million settlement announced by the Utah Attorney General's Office. Spokesman Paul Murphy said the suit against manufacturer Organon USA Inc. and its parent company, Akzo Nobel N.V., was brought...
- Research articles 2004-10-24
- NJBIA Salutes New Jersey's Finest Awards for Excellence: Outstanding Employer Award - Organon Pharmaceuticals USA, Inc.
- President: Michael Novinski NJ Headquarters: Roseland Founded: 1923 NJ Employees: 900 Business: Pharmaceutical Industry Organon considers its employees to be its most important asset. A look at the company's benefits package shows that the company can back up that statement with concrete action. Even in the face of soaring health...
- Research articles 2004-10-01
- The Industry
- Schering-Plough Corp., Kenilworth, NJ, has agreed to acquire Organon BioSciences, including Roseland, NJ-based Organon USA, for approximately $14.4 billion. Through the transaction, which is reportedly expected to close by the end of the year, Schering-Plough will gain Organon's currently marketed products plus five compounds in phase III development. In other...
- Research articles 2007-05-01
- Akzo Nobel's Business Unit Organon Establishes Its International Headquarters in USA
- Business Editors ARNHEM/OSS, the Netherlands--BUSINESS WIRE--April 25, 2001 Organon, the pharmaceutical business unit of Akzo Nobel plans to establish its international headquarters in New Jersey, USA. In the course of 2002 a number of strategic international functions - including the executive team - will transfer to New Jersey...
- Research articles 2001-04-25
- Missouri announces settlement with anti-depressant drug maker
- Missourians who bought the anti-depressant drug Remeron could soon receive refunds under a nationwide settlement announced Monday by Attorney General Jay Nixon. Nixon and attorneys general from across the nation filed a preliminary settlement with drug maker Organon USA Inc. and its parent company, Akzo Nobel N.V., in New Jersey...
- Research articles 2004-10-29
- Implantable contraceptive approved
- U.S. women who want a long-lasting contraceptive that they don't have to think about will have a new option beginning late next month. Implanon, a matchstick-sized rod implanted under the skin of a woman's upper arm, releases a continuous low dose of progestin, a hormone, for three years. Organon...
- Research articles 2006-07-19
- Prudential sells 440,000 SF Essex office building - square foot - Essex County, New York - Brief Article
- Prudential Insurance Company of America has sold a 440,000 SF office building -- one of three that forms a suburban Essex County campus -- to the expanding pharmaceutical manufacturer Organon USA.
- Research articles 2001-07-04
- Fast-track review for Arixtra sNDA in USA.
- Organon and Sanofi-Synthelabo's Arixtra fondaparinux sodium has been awarded a six-month priority review by the US Food and Drug Administration for a new indication, the prophylaxis of deep venous thrombosis, which may lead to pulmonary embolism, in patients undergoing hip fracture surgery, including extended prophylaxis. The supplemental New Drug Application...
- Research articles 2003-03-10
- Attorney General Curran announces Remeron settlement for consumers.
- M2 PRESSWIRE-21 October 2004-MARYLAND ATTORNEY GENERAL: Attorney General Curran announces Remeron settlement for consumersC1994-2004 M2 COMMUNICATIONS LTD RDATE:10212004 Attorney General J. Joseph Curran Jr. today announced completion of a proposed $36 million nationwide settlement for consumers, state purchasers, and other...
- Research articles 2004-10-21
- Motley Rice and D'Arcy, Johnson, Shober & Hassell file Lawsuit Alleging Wrongful Death of a 32-Year-Old Mother of Two Using NuvaRing® Contraceptive
- Organon USA, Inc. and Numerous Other Defendants Named in Complaint Filed in NJ Superior Court MOUNT PLEASANT, S.C. -- Motley Rice LLC and D'Arcy, Johnson, Shober & Hassell, P.C., have filed a wrongful death and survival action against the makers, manufacturers, distributors and marketers of the contraceptive NuvaRing([R]) alleging...
- Research articles 2008-03-20
- Diosynth Biotechnology Appoints New President
- RESEARCH TRIANGLE PARK, N.C. -- Jacques van Kimmenaede has been appointed President of Diosynth Biotechnology in RTP, NC, USA. He joins Diosynth Biotechnology from Organon where he held senior executive management positions in manufacturing and global marketing. Van Kimmenaede, who joined Organon in 1986, served as general manager in...
- Research articles 2007-01-26
- Frank J. Tielens Appointed to President and CEO of Diosynth Biotechnology
- RESEARCH TRIANGLE PARK, N.C. -- Akzo Nobel has announced the appointment of Frank Tielens to President and CEO of Diosynth Biotechnology in Research Triangle Park, NC, USA. Mr. Tielens joins the company from Organon Germany GmbH where he held the position of General Manager. Frank Tielens, who joined Akzo...
- Research articles 2005-05-12
- Generic Remeron
- Teva Pharmaceuticals USA has introduced mirtazapine tablets, AB rated and bioequivalent to Remeron (N.V. Organon). The product is available in 30-count bottles of 15 and 30 mg.
- Research articles 2003-02-17
- Barr Pharmaceuticals receives tentative approval while ID Biomedical gets the green light.
- M2 PRESSWIRE-10 January 2005-FNWU: Barr Pharmaceuticals receives tentative approval while ID Biomedical gets the green lightC1994-2005 M2 COMMUNICATIONS LTD RDATE:01102005 Biotechnology industry news provided by Financial News USA (OTC: FNWU). Barr Pharmaceuticals Inc. reported (NYSE: BRL) that its Barr Laboratories...
- Research articles 2005-01-10
- << Previous
- page 1 of 1
- Next >>
Presented by American Express